Issued 2026-08-13 at $11.97 · now $12.33 (2026-08-13, +3.0% since)
Based on its own history, a month from the 2026-08-13 close, TLX has typically landed between $9.28 and $15.07 — a range of −22.5% to +25.9% from the issuance price $11.97.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
415 overlapping 1 month windows · 2024-11-14 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($11.97) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TLX has typically landed a month from the 2026-08-13 close of $11.97 — the range is history, not a prediction.
- now $12.33 (+3.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.66 (-2.6%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $10.56–$12.76
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $9.28–$15.07
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2025-07-22 | −32.6% | −33.5% | +0.0% |
| 2025-07-11 | −31.8% | −31.8% | +3.3% |
| 2025-07-21 | −31.5% | −34.4% | +0.0% |
| 3 best | |||
| 2026-03-12 | +42.5% | −0.5% | +42.5% |
| 2026-06-03 | +38.5% | +0.0% | +38.5% |
| 2026-03-11 | +36.5% | +0.0% | +36.5% |
415 overlapping windows · 2024-11-14 – 2026-08-13 · not cherry-picked
Pending catalysts
- January 2027 — Trial primary completion: Phase 3 primary completion: PSMA PET Combined With MRI for the Detection of PCa (source, as of 2026-08-14)
- July 2027 — Trial primary completion: Phase 3 primary completion: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma (source, as of 2026-08-14)
- 2027-08-31 — Trial primary completion: Phase 3 primary completion: Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC (source, as of 2026-08-14)
- December 2027 — Trial primary completion: Phase 3 primary completion: The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~2 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.